Capital News

CD BioSciences Introduces First-in-Human (FIH) Study Service for Clinical Trials

 Breaking News
  • No posts were found

CD BioSciences Introduces First-in-Human (FIH) Study Service for Clinical Trials

December 24
19:39 2020
CD BioSciences, a professional US provider of integrated solutions for clinical trials development, has introduced first-in-human (FIH) study service to biological and pharmaceutical institutes and companies for drug development needs.

New York, USA – December 24, 2020 – CD BioScicences, a supplier of whole lifecycle clinical trial services, introduces its first-in-human (FIH) study service to worldwide scientists in biological and pharmaceutical institutes and companies who are in need of a capable hand in expediting their clinical programs.

First-in-human (FIH) studies are a critical step in drug development process and play a key role in supporting the rapid progression of clinical trials. The design of FIH studies is typically to characterize a candidate drug’s pharmacokinetics, potential effective concentration or dose, and molecule safety and tolerability. Although a common consensus on the design and conduct of FIH studies is not available, approaches that could enhance the candidate drug’s predictive nature and FIH studies’ adaptive nature could greatly accelerate the drug development.

With a team of experienced professionals in clinical pharmacology, safety evaluation, formulation, clinical development and operation, toxicological assessment and regulatory affairs, CD BioSciences provides safety-oriented FIH studies including study design, study conduction, analyzing and reporting. The company is committed to provide stringent participant oversight in conducting various ascending dose studies.

“Safety is our priority.” Says Helen James, Senior Scientist of CD BioSciences. “With over 10 years of experience in early clinical trial conduction, our scientist team are confident to meet our clients’ specific requirements and help achieve their development goals for regulatory submission purpose.”

CD BioSciences sets no limitation in the therapeutic areas for its FIH study service. It provides FIH studies for various compounds including small molecules, therapeutic antibodies, cellular therapies, gene therapies, and etc. To learn more about this service or have a better understanding of the company, visit the company’s website (https://www.cd-biosciences.com) for detailed information. Also, any service inquiry concerned with clinical trials could be sent to [email protected]. The company operates in regular business hours from 9:00 am to 6:00 pm, Monday to Friday.

About CD BioSciences

Founded in 2004 in the US, CD BioSciences has been providing a full range of clinical trial consulting, study design, conduction, management, data analysis and report writing services for over a decade. Professional and quality work has won the company credits in biological and pharmaceutical industry. Except for FIH studies, the company also excels at clinical services such as bioanalytical lab testing, clinical pharmacology, early phase trials, and later phase trials. CD BioSciences is a customer-centered company and it’s intended to reduce as much as of the clients’ time and cost in drug development.

Media Contact
Company Name: CD BioSciences
Contact Person: Michelle Moser
Email: Send Email
Phone: 1-315-636-4280
Country: United States
Website: https://www.cd-biosciences.com


Warning: count(): Parameter must be an array or an object that implements Countable in /home/capitalnews/public_html/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share